ARCHIVES

Memorial’s Scher Warns FDA About Flaws In Provenge Data, Urges Not To Approve.

This article is from The Cancer Letter archive.

Vol. 33 No. 14 | April 13, 2007

Download PDF Visit The Full Archive

Related Articles

Preoperative Chemo Doubles Survival In Locally Advanced Bladder Cancer

May 25, 2001

O’Leary Leads RPCI’s OR;

February 8, 2002

In Brief: Clinical Education Program to Be Phased Out; Ken Endicott Retires From Grupenhoff Firm

January 31, 1986

Clinical Trials Approved By NCI CTEP Last Month

May 27, 2011

Bristol No Longer Needs Yew From Public Lands, Official Says; Will Use Processed Needles

January 29, 1993

NCI Programs: Advisors Approve Recompetition of Phase II Contracts

July 9, 1999